Real-time Continuous Glucose Monitoring Compared With Intermittent Continuous Glucose Monitoring in People With Type 2 Diabetes Treated With Insulin.

NCT ID: NCT07308925

Last Updated: 2025-12-30

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 108 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-31
• Study Completion Date: 2028-12-30

Brief Summary

The objective is to compare the efficacy of TR-CGM versus isCGM in patients diagnosed with T2D who are treated with insulin and use CGM, as defined by time in range between 70 and 180 mg/dL.

An open-label clinical trial will be conducted. Patients with T2D who use intermittent glucose monitoring and insulin with poor metabolic control will be included. They will be randomized to continue with isCGM or RT-CGM.

The primary outcome: %TIR 70-180 mg/dL.

Detailed Description

All patients diagnosed with type 2 diabetes (T2D) who meet the inclusion criteria will be identified (see inclusion and exclusion criteria). They will then be invited to participate in the study and asked to sign an informed consent form. Demographic data, baseline clinical characteristics, and clinical tests related to metabolic control will be collected.

Visit 0 (V0): Informed consent signature and basal CGM system installation will be verified.

Visit 1 (V1): CGM data will be downloaded. All enrolled patients will receive the same instructions for device use and management of high and low glucose levels, according to standard clinical procedures. Then, randomization will be performed by someone who is blinded to the clinical characteristics of each patient and is not part of the research group. The allocation given by this mechanism cannot be changed by the treating physicians.

• Usual care + TR-CGM group: Patients in this group will receive a continuous interstitial glucose monitoring (CIGM) sensor via the FreeStyle Libre 2 Plus device and LibreLink app® (Abbott Diabetes Care, Inc., Alameda, CA). High alarms greater than 250 mg/dL and low glucose alerts less than 70 mg/dL will be programmed. All participants will be instructed to change their sensor according to the manufacturer's recommendations: every 15 days for the TR-CGM group.
• Usual care + CIGM group: Patients in this group will receive a CIGM sensor using the FreeStyle Libre 2 device (Abbott Diabetes Care Inc., Alameda, CA, USA). High alarms >250 mg/dL and low glucose alerts <70 mg/dL will be programmed. Additionally, they will be instructed to perform at least eight scans daily to avoid data loss. All participants were instructed to change their sensors according to the manufacturer's recommendations: every 15 days for isCGM.

Standard Care (Applies to Both Groups):

All patients should be assessed by the diabetes clinic's nutrition service, which will provide basic dietary and physical activity recommendations.

All patients will be instructed in basal and/or prandial insulin titration, as appropriate.

Conditions

Type 2 Diabetes

Keywords

Type 2 Diabetes; Continuous Glucose Monitoring; Time in Range

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

isCGM

Usual Care + isCGM Group: Patients in this group will have the FreeStyle Libre 2 continuous interstitial glucose monitoring sensor (Abbott Diabetes Care Inc., Alameda, CA, USA) inserted. High glucose alarms (\>250 mg/dL) and low glucose alerts (\<70 mg/dL) will be programmed. They will also be instructed to perform at least eight scans daily to avoid data loss. All participants were instructed to replace their sensors according to the manufacturer's recommendations: every 15 days for isCGM.

Group Type: NO_INTERVENTION

No interventions assigned to this group

RT-CGM

• Usual care + TR-CGM group: Patients in this group will undergo insertion of a continuous interstitial glucose monitoring (CGM) sensor using the FreeStyle Libre 2 Plus device and LibreLink app® (Abbott Diabetes Care, Inc., Alameda, CA, USA). The sensor will be programmed with high glucose alarms (\>250 mg/dL) and low glucose alerts (\<70 mg/dL). All participants will be instructed to replace their sensor according to the manufacturer's recommendations: every 15 days for TR-CGM.

Group Type: EXPERIMENTAL

real time Continuous Glucose Monitoring

Intervention Type: DEVICE

• Usual care + TR-CGM group: Patients in this group will undergo insertion of a continuous interstitial glucose monitoring (CGM) sensor using the FreeStyle Libre 2 Plus device and LibreLink app® (Abbott Diabetes Care, Inc., Alameda, CA, USA). The sensor will be programmed with high glucose alarms (\>250 mg/dL) and low glucose alerts (\<70 mg/dL). All participants will be instructed to replace their sensor according to the manufacturer's recommendations: every 15 days for TR-CGM.

Interventions

real time Continuous Glucose Monitoring

• Usual care + TR-CGM group: Patients in this group will undergo insertion of a continuous interstitial glucose monitoring (CGM) sensor using the FreeStyle Libre 2 Plus device and LibreLink app® (Abbott Diabetes Care, Inc., Alameda, CA, USA). The sensor will be programmed with high glucose alarms (\>250 mg/dL) and low glucose alerts (\<70 mg/dL). All participants will be instructed to replace their sensor according to the manufacturer's recommendations: every 15 days for TR-CGM.

Intervention Type: DEVICE

Other Intervention Names

RT-CGM

Eligibility Criteria

Inclusion Criteria

• Minimum age of 35 years.
• HbA1c >7.0%
• Treatment with one or more insulin injections.
• Stable medication regimen for the 3 months prior to study entry.
• Insulin treatment for ≥3 months with a stable dose prior to entry, with fasting blood glucose between 70 and 130 mg/dL.
• Availability of an NFC-enabled smartphone.

Exclusion Criteria

• Pregnancy or planning to become pregnant during the study period.
• History of bariatric surgery within the year prior to study entry or plans to undergo bariatric surgery during the study.
• Having a condition that would likely require an MRI during the study period.
• Use of medications containing high doses of ascorbic acid (>2000 mg/day), as it may falsely increase sensor readings.
• Concomitant illness or condition that may compromise patient safety, including, but not limited to, serious mental illness, a diagnosed or suspected eating disorder, or any long-term medical/unmanageable disorder.
• GFR less than 30 ml/min.
• Psychiatric condition that interferes with study-related tasks.
• Known (or suspected) significant allergy to medical-grade adhesives.

• Minimum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pontificia Universidad Javeriana

OTHER

Sponsor Role: collaborator

Hospital Universitario San Ignacio

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Diana C Henao-Carrillo, Endocrinologyst

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario San Ignacio

Locations

Hospital Universitario San Ignacio

Bogotá, , Colombia

Countries

Colombia

Central Contacts

Diana C Henao, Endocrinologyst

Role: CONTACT

Phone: +57 601 5946161

Email: dchenao@husi.org.cp

Adriana L Gonzáles, Nutricionist

Role: CONTACT

Phone: +57 601 5946161

Email: algomez@husi.org.co

Facility Contacts

Diana C Henao-Carrillo, Endocrinologyst

Role: primary

Adriana G Gómez-Velasquez, Nutricionist

Role: backup

Other Identifiers

FM-CIE-1013-24

Identifier Type: -

Identifier Source: org_study_id